2017_SBRT_Course Book

Oligometastatic NSCLC without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study

Local consolidative therapy regimens used • Hypofractionated RT or SABR in 48% (12 patients) • Surgery and RT for 24% • Chemo-RT for 8% • Hypofractionated RT and CT-RT for 12% • Surgery only for 4%

Progression-free survival

11·9 months (90% CI 5·72–20·90) versus 3·9 months (2·30–6·64) in the maintenance group (HR 0·35 [90% CI 0·18–0·66]; log-rank p=0·0054).

Gomez D, Lancet Oncol 2016